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BACKGROUND: This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference
trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU), when each was given with paclitaxel as first-line
treatment for HER2-positive metastatic breast cancer.
METHODS: Between 4 April 2014 and 22 January 2016, 707 participants were randomised 1:1 to receive intravenous PF-05280014
plus paclitaxel (PF-05280014 group; n= 352) or trastuzumab-EU plus paclitaxel (trastuzumab-EU group; n= 355). PF-05280014 or
trastuzumab-EU was administered weekly (first dose 4mg/kg, subsequent doses 2 mg/kg), with the option to change to a 3-weekly
regimen (6 mg/kg) from Week 33. Treatment with PF-05280014 or trastuzumab-EU could continue until disease progression.
Paclitaxel (starting dose 80mg/m2) was administered on Days 1, 8 and 15 of 28-day cycles for at least six cycles or until maximal
benefit of response. The primary endpoint was objective response rate (ORR), evaluating responses achieved by Week 25 and
confirmed by Week 33, based on blinded central radiology review.
RESULTS: The risk ratio for ORR was 0.940 (95% CI: 0.842–1.049). The 95% CI fell within the pre-specified equivalence margin of
0.80–1.25. ORR was 62.5% (95% CI: 57.2–67.6%) in the PF-05280014 group and 66.5% (95% CI: 61.3–71.4%) in the trastuzumab-EU
group. As of data cut-off on 11 January 2017 (using data up to 378 days post-randomisation), there were no notable differences
between groups in progression-free survival (median: 12.16 months in the PF-05280014 group vs. 12.06 months in the trastuzumab-EU
group; 1-year rate: 54% vs. 51%) or overall survival (median: not reached in either group; 1-year rate: 89.31% vs. 87.36%). Safety
outcomes and immunogenicity were similar between the treatment groups.
CONCLUSION: When given as first-line treatment for HER2-positive metastatic breast cancer, PF-05280014 plus paclitaxel
demonstrated equivalence to trastuzumab-EU plus paclitaxel in terms of ORR.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01989676
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BACKGROUND
Trastuzumab is a recombinant, humanised, monoclonal antibody
that targets a juxta-membrane epitope in subdomain IV of the
human epidermal growth factor receptor 2 (HER2) extracellular
domain (ECD). Trastuzumab has been shown in both in vitro and
in vivo assays to inhibit the proliferation of HER2-overexpressing
human tumour cells, and it is a potent mediator of antibody-
dependent cell-mediated cytotoxicity.1,2 Clinically, trastuzumab is
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used in the treatment of HER2-overexpressing breast and gastric
cancers.1,2 Compared with chemotherapy alone, the addition of
trastuzumab to chemotherapy has been associated with survival
benefits in both early-stage and metastatic breast cancer (MBC),3,4
as well as gastric cancer.5 However, physicians have reported
barriers to patients accessing trastuzumab, which may result in
suboptimal treatment.6
Biosimilars—biological products that are highly similar to a
licensed reference (i.e., originator) biologic—provide additional
treatment options that may expand access to biologics such as
trastuzumab.6 To gain regulatory approval, a potential biosimilar
must be shown to have no clinically meaningful differences in
quality attributes, efficacy or safety compared with the originator
product.7–9 Biosimilars are developed in a stepwise process that
involves head-to-head comparison with the originator, and
biosimilarity is determined based on the totality of evidence from
analytical, nonclinical and clinical studies.7–9
The humanised monoclonal antibody PF-05280014 is a
biosimilar to the trastuzumab reference product Herceptin®. In
the European Union (EU), PF-05280014 has been authorised under
the name Trazimera™ (Pfizer Europe MA EEIG, Sandwich, UK) for
the same indications as reference trastuzumab.2,10 PF-05280014
has an identical amino acid sequence to reference trastuzumab,
and has demonstrated similarity in comparative structural,
functional and nonclinical in vivo studies.11 Furthermore, a
single-dose comparative study in healthy male volunteers
established similarity in pharmacokinetics (PK),12 and a compara-
tive trial in the neoadjuvant HER2-positive (HER2+) breast cancer
setting evaluated PK, efficacy, safety and immunogenicity.13
As the final step in the biosimilarity assessment, we conducted
the current study (REFLECTIONS B327–02) to compare the efficacy,
safety and immunogenicity of PF-05280014 and reference
trastuzumab (Herceptin®) sourced from the EU (trastuzumab-EU),
each in combination with paclitaxel, as first-line treatment for
patients with HER2+MBC. The primary objective was to compare
objective response rate (ORR) in the two treatment groups, testing
the hypothesis that the risk ratio for ORR was within a pre-
specified equivalence margin. Here, we report results of the
primary efficacy analysis, conducted after all patients had
completed Week 33 tumour assessments (or discontinued study
treatment earlier). We also present secondary analyses based on a
later data cut-off date, when all patients had completed Week 53
tumour assessments (or discontinued study treatment earlier).
METHODS
Study design and participants
This is an ongoing, international, randomised, double-blind,
parallel-group study (ClinicalTrials.gov: NCT01989676; EudraCT:
2013-001352-34). Patients were randomised at 143 sites across 24
countries (Argentina, Brazil, Chile, Czech Republic, Greece,
Hungary, India, Japan, Latvia, Mexico, Peru, Philippines, Poland,
Portugal, Republic of Korea, Romania, Russian Federation, Serbia,
Slovakia, South Africa, Thailand, Turkey, Ukraine, and the United
States).
Eligible patients were females aged ≥ 18 years with metastatic,
histologically confirmed breast cancer with at least one measur-
able lesion as defined by Response Evaluation Criteria in Solid
Tumours (RECIST) 1.1. Patients were required to have documented
HER2+ status according to one of the following: HER2 gene
amplification by fluorescent in-situ hybridisation (FISH), chromo-
genic in-situ hybridisation (CISH) or dual in-situ hybridisation
(DISH), with amplification defined per the manufacturer’s kit
instruction; HER2 overexpression by immunohistochemistry (IHC)
categorised as IHC3+; or HER2 overexpression by IHC categorised
as IHC2+, with FISH, CISH or DISH confirmation. For study entry,
HER2+ status could be established via local or central laboratory
assessment; however, all patients were required to have available
tumour tissue for central review of HER2 status (see Supplemen-
tary Methods S1 for additional details on determination of HER2
positivity). Patients had documented oestrogen receptor (ER)
status (positive or negative) based on local or central laboratory
assessment. Additionally, patients were required to have an
Eastern Cooperative Oncology Group performance status of 0–2,
screening laboratory values within specified limits, and left
ventricular ejection fraction (LVEF) within the institution’s normal
range, by echocardiogram or multi-gated acquisition scan.
Exclusion criteria included prior systemic therapy for MBC
(except endocrine therapy); relapse within 1 year of last dose of
previous adjuvant or neoadjuvant treatment (except endocrine
therapy); prior cumulative dose of doxorubicin >400mg/m2 or
epirubicin >800 mg/m2; inflammatory breast cancer; superficial
disease site that could not be assessed radiographically as the
only site of measurable disease; major surgery, radiotherapy or
any investigational agents within 4 weeks prior to the first dose of
study treatment; concurrent administration of other anti-cancer
therapies (other than bisphosphonates or anti-RANK [receptor
activator of nuclear factor kappa B] ligand antibody to control pre-
existing bone metastases); active uncontrolled or symptomatic
central nervous system metastases; and active uncontrolled
cardiac disease.
Based on a retrospective review of patients randomised during
the early part of the study, a requirement for sites to forward
radiographs to the independent central review laboratory to
confirm the presence of measurable disease prior to patient
randomisation was added in a protocol amendment. A full listing
of eligibility criteria is provided in Supplementary Methods S2.
Randomisation and blinding
Using an automated interactive web-based response system,
investigators or their pre-specified designee randomised patients
in a 1:1 ratio to PF-05280014 plus paclitaxel or trastuzumab-EU
plus paclitaxel. Randomisation was stratified by prior trastuzumab
exposure and ER status, with a block size of four. This was
according to a randomisation schedule that was computer-
generated by the sponsor, to which the sponsor’s personnel
directly involved in study conduct were blinded. Patients,
investigators, central radiology reviewers and the sponsor’s study
team were blinded to treatment assignments, and external
packaging for each vial of PF-05280014 or trastuzumab-EU
appeared identical. Safety data were reviewed in an unblinded
manner by an external data monitoring committee throughout
the study (up to the Week 53 milestone). Safety outcomes were
also reviewed by the sponsor’s study team, who were blinded
until database release for the Week 53 analysis.
Treatments
PF-05280014 or trastuzumab-EU was administered weekly (first
dose 4mg/kg, intravenous [IV] infusion over 90min; subsequent
doses 2 mg/kg, infused over 30–90min, depending on tolerability)
on Days 1, 8, 15 and 22 of each 28-day cycle when given in
combination with paclitaxel, and until at least Week 33 (Fig. 1). The
dose and weekly schedule used in the current trial demonstrated
efficacy in a pivotal phase III study of reference trastuzumab in
MBC,3 and is consistent with the labelling for reference
trastuzumab in Europe and the United States.1,2 Following
completion of the paclitaxel administration period, and beginning
no earlier than Week 33, the PF-05280014 or trastuzumab-EU
regimen could be changed at the investigator’s discretion to
6mg/kg, infused over 30–90min every 3 weeks. This approach
ensured consistent treatment during the evaluation period for the
primary efficacy endpoint while allowing for a less-frequent
treatment schedule after this time. Treatment could continue until
disease progression, as assessed by RECIST 1.1, in the judgement
of the investigator. Dose reductions of PF-05280014 and
trastuzumab-EU were not permitted.
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Paclitaxel was administered on Days 1, 8 and 15 of each 28-day
cycle (starting dose 80mg/m2, IV infusion over 60 min). All
patients were to receive premedication for paclitaxel administra-
tion in accordance with local paclitaxel product information and
standard of care. In the absence of disease progression or
unacceptable toxicity in the judgement of the investigator,
paclitaxel treatment was continued for at least six cycles or until
maximal benefit of response was obtained. Depending on toxicity,
provision was made for paclitaxel dose reductions.
Outcomes and assessments
Per regulatory guidance, as a scientific matter, ORR was
considered sufficiently sensitive to detect any clinically mean-
ingful differences in efficacy between PF-05280014 and
trastuzumab-EU in this study population. Thus, the primary endpoint
for the study was ORR, defined as the percentage of patients
in each group with complete or partial response by Week 25
that was confirmed by Week 33, in accordance with RECIST 1.1.
Blinded central radiology review was the basis for the primary
analysis. Secondary efficacy endpoints included duration of
response (DOR; the time from first documentation of objective
tumour response to progressive disease or death), 1-year
progression-free survival (PFS) rate (based on the time from
randomisation to progressive disease or death) and 1-year overall
survival rate (based on the time from randomisation to death). PFS
and DOR evaluations were also based on blinded central radiology
assessments. Additional secondary endpoints to support the
assessment of similarity were safety, peak and trough concentra-
tions of PF-05280014 and trastuzumab-EU at selected cycles and
incidence of antidrug antibodies (ADAs), including neutralising
antibodies (NAbs).
Computed tomography or magnetic resonance imaging scans of
the chest and abdomen, and any other site of disease clinically
indicated, were required at screening. During treatment, tumour
assessments were performed every 8 weeks to Week 41, at Week 53
and then every 12 weeks (or sooner if clinically indicated). The
allowable window for tumour imaging assessments was ± 14 days.
All scans through Week 53 were forwarded for central radiology
review. Patients with tumour response were required to undergo
confirmatory assessments ≥ 4 weeks later. Bone scans were carried
out at screening for all patients, and then repeated during the
treatment phase if clinically indicated or to confirm response if
lesions were identified at screening.
Serum samples for determining peak and trough drug
concentrations were collected at Cycle 1, 3, 4, 5, 7, 8 and
subsequently every 3 cycles until the end-of-treatment visit
(28 days post last study treatment administration). Samples were
collected pre-dose at each scheduled cycle (Week 1 Day 1).
Additional samples were collected during Cycles 1 and 5, 1 h
after the end of infusion (Week 1 Day 1) and pre-dose at Week 2
Day 8. Samples were analysed by QPS LLC (Newark, DE, USA)
using a validated, sensitive and specific enzyme-linked immuno-
sorbent assay (ELISA). Sample concentrations were determined by
interpolation from calibration standard curves in the range
0.500–100 μg/ml. The concentration–time data were used for a
population PK analysis using a nonlinear mixed effect modelling
approach (to be reported separately).
For assessment of ADAs and NAbs, serum samples were
collected pre-dose at Cycle 1, 3, 5, 8 and subsequently every
3 cycles until the end-of-treatment visit. Two electrochemilumi-
nescent immunoassays, one for detecting antibodies against
PF-05280014 and the other for detecting antibodies against
trastuzumab-EU, were used to analyse the samples. Both ADA
assays utilised the same immunoassay platform and were
validated in accordance with draft US Food and Drug Adminis-
tration guidance on assay development and validation for
immunogenicity testing of therapeutic protein products.14 ADA
analyses were conducted by Intertek Pharmaceutical Services (San
Diego, CA, USA), and followed a tiered approach of screening,
confirmation and titre determination.12 If a sample tested positive
for ADA according to the dosed product, the sample was also
tested for cross-reactivity of the ADA against the other product,
using the corresponding assay. Samples testing positive for the
presence of ADAs (anti-PF-05280014 or anti-trastuzumab-EU) were
further analysed for NAbs. NAb analyses were conducted by QPS
LLC (Newark, DE, USA), using validated competitive binding
assays.
Additionally, serum samples were collected pre-dose at Cycle 1,
3, 5, 8 and at the end-of-treatment visit, and analysed by Q2
Solutions (Morrisville, NC, USA) for soluble, shed HER2 ECD
concentrations using a HER2 ELISA development kit (Nuclea
Diagnostics, Pittsfield, MA, USA).
Safety was characterised by the type, incidence, severity, timing,
seriousness and relationship to study treatment of adverse events
(AEs) and laboratory abnormalities. Additional evaluations
included vital signs, 12-lead electrocardiograms and LVEF assess-
ment by echocardiogram or multi-gated acquisition scan.
Investigators recorded AEs, their severity (graded in accordance
with the National Cancer Institute Common Terminology Criteria
for Adverse Events version 4.0315) and the investigator’s opinion
of their relationship to study treatment. Medical Dictionary for
Regulatory Activities v19.1 coding was applied. Signs and
symptoms of infusion-related reactions (IRRs) were defined as
such by the investigator on the AE reporting form, in addition to
the investigator recording a separate AE of IRR. AEs of special
interest were identified based on the established safety profile of
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Fig. 1 Study design. PF-05280014 or trastuzumab-EU: administered weekly (4 mg/kg loading dose on Cycle 1 Day 1; subsequent doses
2mg/kg) on Days 1, 8, 15 and 22 of each 28-day cycle during the paclitaxel administration period and until at least Week 33. Following
completion of the paclitaxel administration period and beginning no earlier than Week 33, the PF-05280014 or trastuzumab-EU regimen could
be changed to 6mg/kg every 3 weeks. Treatment with PF-05280014 or trastuzumab-EU could continue until disease progression. Paclitaxel:
administered on Days 1, 8 and 15 of each 28-day cycle (starting dose 80mg/m2, with provision for dose reduction). In the absence of disease
progression or unacceptable toxicity in the judgement of the investigator, paclitaxel treatment was continued for ≥ 6 cycles or until maximal
benefit of response was obtained. On days when both treatments were administered, the order of administration was PF-05280014 or
trastuzumab-EU infusion followed by paclitaxel infusion. aFollow-up to assess survival status continued until death or until 1 year from
randomisation and ≥ 6 months following last dose of study treatment. HER2+ human epidermal growth factor receptor 2-positive, MBC
metastatic breast cancer, trastuzumab-EU reference trastuzumab sourced from the European Union
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reference trastuzumab,1,2 with the listing finalised prior to the data
cut-off for the primary efficacy analysis. Treatment-emergent AEs
(TEAEs) were those that occurred (or worsened, if pre-existing)
after the beginning of study treatment through 70 days after the
last dose. Serious AEs (SAEs) were those that resulted in death,
were life-threatening, required hospitalisation (or prolongation of
existing hospitalisation) or resulted in disability, incapacity or
congenital abnormality.
After treatment discontinuation, patient survival status was
collected by telephone every 2 months until death or until 1 year
from randomisation and ≥ 6 months following last dose of study
treatment.
Statistical analyses
The primary efficacy (Week 33) analysis was prospectively planned
to be performed after all randomised patients had received
treatment to Week 25 and undergone assessment for confirma-
tion of response by Week 33, or discontinued study treatment
before Week 33. Similarity between PF-05280014 and
trastuzumab-EU was demonstrated if the 95% confidence interval
(CI) of the risk ratio for ORR was within a pre-specified equivalence
margin of 0.80–1.25, as per the method proposed by Miettinen
and Nurminen.16 The equivalence margin was derived from a
publication-level meta-analysis (unpublished) of three randomised
studies of reference trastuzumab used in combination with
taxanes.3,17,18 Using a random effect model, the overall estimated
log-transformed risk ratio of ORR of chemotherapy alone over
trastuzumab plus chemotherapy was −0.54, with a one-sided 90%
upper confidence bound of −0.32. A 75% fraction of the upper
bound was taken, resulting in a log-transformed risk ratio of
−0.24. This value was exponentiated to a risk ratio of 0.79, which
corresponded to a margin of 0.79–1.27 for equivalence testing; the
more conservative range of 0.80–1.25 was used. Assuming an ORR
of 60% in both treatment groups (a conservative estimate based
on a separate, unpublished, publication-level meta-analysis), a
sample of 630 patients (n= 315/arm) provided ~85% power to
demonstrate equivalence with a 2.5% type 1 error rate. Allowing
for 10% attrition, a total of 690 randomised patients (n= 345/arm)
was planned. With an estimated ORR of 60% in the trastuzumab-EU
group and a sample of 630 patients, the chosen margin would result
in an ORR acceptance range of 55.0–66.4% in the PF-05280014
group for claiming equivalence. This acceptance range for ORR was
considered to be clinically acceptable for determining similarity in
the efficacy of PF-05280014 and trastuzumab-EU.
For the ORR calculation, if a patient had a missing tumour
outcome that prevented the derivation of best overall response,
the patient was considered a non-responder. The primary analysis
was repeated with the additional stratification variables to assess
whether prior trastuzumab exposure or ER status would affect the
risk ratio; response rates based on investigator assessments were
also calculated. Additionally, in a post-hoc analysis, the risk
difference for ORR was calculated, along with its 95% CI.
The secondary (Week 53) analyses presented were based on
clinical data collected up to 378 days post-randomisation, as of a
cut-off date when all patients had either completed Week 53
tumour assessments or discontinued study treatment earlier. For
secondary efficacy endpoints, the Kaplan–Meier method was used
to estimate PFS rate, overall survival rate and DOR, and a log-rank
test stratified by prior trastuzumab exposure and ER status was
used to compare the treatments. Hazard ratios (HRs) and 95% CIs
based on a Cox proportional hazard model with stratification by
prior trastuzumab exposure and ER status were presented. For
time-to-event endpoints, missing data were censored. Safety data
were summarised using descriptive statistics, as were serum drug
and HER2 ECD concentration–time data. The percent change from
baseline in serum HER2 ECD concentrations was also calculated.
The percentage of patients with positive ADA and NAb results was
summarised for each treatment group.
The intent-to-treat (ITT) population, defined as all patients
randomised to study treatment, was used for the efficacy analyses.
The per protocol (PP) population was defined as all patients with
no major protocol deviations who had HER2+MBC as confirmed
by central review, measurable disease at baseline as confirmed by
central review, and who were randomised and received study
treatment as planned per protocol. The PP population was used
for sensitivity analyses of efficacy outcomes (using the statistical
methods outlined above) and for evaluation of serum soluble
HER2 ECD levels. The safety population, defined as all patients
who received at least one dose of study treatment, was used for
safety and immunogenicity analyses. The PK population was defined
as all patients treated with PF-05280014 or trastuzumab-EU
who had no major protocol deviations that influenced
PK assessments and had at least one postdose concentration
measurement.
No interim analysis was planned. As the study is ongoing, the
data presented are based on two pre-planned analyses conducted
for the Week 33 and Week 53 milestones while the study database
remains open; database lock will take place when long-term
follow-up is complete.
A statement on the availability of study data can be found in
the “Additional Information” section.
RESULTS
Patient disposition and baseline characteristics
Of the 973 patients screened, 707 patients were randomised to
PF-05280014 plus paclitaxel (PF-05280014 group; n= 352) or
trastuzumab-EU plus paclitaxel (trastuzumab-EU group; n= 355)
between 4 April 2014 and 22 January 2016, and comprised the ITT
population. In total, 439 (62.1%) of the 707 enrolled patients were
randomised per the protocol amendment that required sites to
obtain central confirmation of measurable disease before treatment
allocation (222 [63.1%] patients in the PF-05280014 group and 217
[61.1%] patients in the trastuzumab-EU group). Five patients were
randomised but did not receive study treatment (three in the
PF-05280014 group and two in the trastuzumab-EU group). Figure 2
summarises the populations analysed and patient dispositions,
which were similar between the treatment groups. Baseline
characteristics and demographics were well-balanced (Table 1).
The data cut-off date for the primary efficacy analysis was
24 August 2016. Of the 702 patients who received study
treatment, 538 (76.6%) were exposed to at least eight cycles of
treatment with PF-05280014 (266 [76.2%] patients) or
trastuzumab-EU (272 [77.1%] patients). The data cut-off date for
the secondary (Week 53) analyses presented was 11 January 2017.
At that time, 536 (75.8%) of the 707 randomised patients
remained ongoing in the study: 336 (47.5%) were still being
actively treated with PF-05280014 or trastuzumab-EU, and 200
(28.3%) had discontinued treatment but were being followed
for survival. The primary reason for discontinuing treatment with
PF-05280014 or trastuzumab-EU was objective disease progres-
sion (138 [39.2%] vs. 143 [40.3%] patients, respectively).
Efficacy
In the primary efficacy analysis, the risk ratio for ORR by Week 25
(confirmed by Week 33) in the ITT population was 0.940
(PF-05280014 group over trastuzumab-EU group), with a 95% CI
of 0.842–1.049. Hence, the pre-specified definition of similarity
between PF-05280014 and trastuzumab-EU was met. ORR was
62.5% (95% CI: 57.2–67.6%) in the PF-05280014 group and 66.5%
(95% CI: 61.3–71.4%) in the trastuzumab-EU group (Table 2). The
risk difference for ORR (PF-05280014 group minus trastuzumab-EU
group) was −4.0% (95% CI: −11.0% to 3.1%). Sensitivity analyses
using stratification factors, the PP population and investigator-
rated assessments all supported results of the primary analysis
(Supplementary Tables S1–S3).
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3 did not receive treatment
1 leucoerythroblastic syndrome
1 thrombocytopenia
1 did not meet eligibility criteria
279 ongoing in study
187 receiving PF-05280014
  92 no longer receiving PF-05280014 
but remaining in long-term follow-up
16 discontinued PF-05280014
15 objective progression or relapse
  1 global deterioration of health status
4 discontinued paclitaxela
2 discontinued from study
2 died
9 completed studyb
59 discontinued from study
38 died
  7 lost to follow-up
14 withdrew consent
11 completed studyb
352 analysed for efficacy (ITT population)
280 analysed for efficacy (per protocol 
populationd)
349 analysed for PK (PK population)
349 analysed for safety (adverse events)
348 analysed for safety (laboratory data)
162 discontinued PF-05280014
123 objective progression or relapse
    3 global deterioration of health status
  15 adverse event(s)
    3 died
    1 protocol violation
    1 lost to follow-up
    9 withdrew consent
    7 other
144 discontinued paclitaxela
2 did not receive treatment
1 withdrew consent
1 did not meet eligibility criteria
17 discontinued trastuzumab-EU
16 objective progression or relapse
  1 other
5 discontinued paclitaxela
5 discontinued from study
4 died
1 lost to follow-up
6 completed studyb 
68 discontinued from study
38 died
11 lost to follow-up
19 withdrew consent
  6 completed studyb
171 discontinued trastuzumab-EU
127 objective progression or relapse
    4 global deterioration of health status
  11 adverse event(s)
  10 died
    4 protocol violation
    2 lost to follow-up
    9 withdrew consent
    4 other
138 discontinued paclitaxela
973 assessed for eligibility
266 excluded
352 allocated to PF-05280014 + paclitaxel
349 received treatment
707 randomised
268 ongoing in study
171 receiving PF-05280014
  97 no longer receiving PF-05280014
but remaining in long-term follow-up
279 ongoing in study
182 receiving trastuzumab-EU
  97 no longer receiving trastuzumab-EU 
but remaining in long-term follow-up
355 analysed for efficacy (ITT population)
285 analysed for efficacy (per protocol 
populationd)
353 analysed for PK (PK population)
353 analysed for safety (adverse events)
351 analysed for safety (laboratory data)
355 allocated to trastuzumab-EU + paclitaxel
353 received treatment
268 ongoing in study
165 receiving trastuzumab-EU
103 no longer receiving trastuzumab-EU
but remaining in long-term follow-up
Data cut-off for
secondary
(Week 53) analysesc
Data cut-off for
primary efficacy
(Week 33) analysisc
Safety population/
PK population
ITT population
Fig. 2 Study profile. Primary efficacy analysis based on a data cut-off date (24 August 2016) when all patients had either completed Week 33
tumour assessments or discontinued study treatment earlier. Secondary analyses based on a data cut-off date (11 January 2017) when all
patients had either completed Week 53 tumour assessments or discontinued study treatment earlier. aNumber does not include patients who
completed treatment with paclitaxel per protocol. bPatients who completed all follow-up as required by the protocol. cStatus at time of data
cut-off, using data up to 378 days post-randomisation. dReasons for exclusion from the per protocol population were comparable between the
groups. The most frequent reason for exclusion was “no measurable disease at baseline per central reviewer” (31 [8.8%] patients in the PF-
05280014 group vs. 25 [7.0%] patients in the trastuzumab-EU group), followed by “missing, not evaluable or equivocal HER2 status by central
laboratory” (27 [7.7%] vs. 25 [7.0%] patients). HER2 human epidermal growth factor receptor 2, ITT intent-to-treat, PK pharmacokinetics,
trastuzumab-EU reference trastuzumab sourced from the European Union
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In the Week 53 analysis, disease progression or death in the
ITT population was reported for 144 (40.9%) patients in
the PF-05280014 group and 148 (41.7%) patients in the
trastuzumab-EU group. The corresponding estimated 1-year PFS
rates were 54% (95% CI: 48–60%) and 51% (95% CI: 45–57%), and
median times to PFS were 12.16 (95% CI: 11.93–12.48) months and
12.06 (95% CI: 11.79–not estimable) months (Fig. 3a). The HR for
PFS was 1.00 (95% CI: 0.80–1.26), and the stratified log-rank test
resulted in a one-sided P-value of 0.505, indicating no statistically
significant difference between treatments. Estimated 1-year
overall survival rates were 89.31% (95% CI: 85.48–92.17%) in the
PF-05280014 group and 87.36% (95% CI: 83.27–90.51%) in the
trastuzumab-EU group; it was not possible to estimate the median
time to death, owing to too few events (Fig. 3b). The HR for overall
survival was 1.004 (95% CI: 0.655–1.539; log-rank P= 0.507).
Median DOR was 11.27 (95% CI: 10.41–11.27) months in the
PF-05280014 group and 10.58 (95% CI: 10.22–not estimable)
months in the trastuzumab-EU group. The HR for DOR was 0.92
Table 1. Baseline demographic and other characteristics (ITT population)
PF-05280014 plus paclitaxel
(n= 352)
Trastuzumab-EU plus paclitaxel
(n= 355)
Total
(N= 707)
Age, years
Mean (SD) 54.0 (10.8) 54.1 (10.9) 54.1 (10.8)
Median (range) 55.0 (19–80) 54.0 (25–85) 54.0 (19–85)
Weight, kg
Mean (SD) 69.1 (17.1) 68.1 (16.1) 68.6 (16.6)
Median (range) 68.2 (29–147) 66.0 (36–139) 67.0 (29–147)
Race, n (%)
White 232 (65.9) 244 (68.7) 476 (67.3)
Black 5 (1.4) 8 (2.3) 13 (1.8)
Asian 104 (29.5) 84 (23.7) 188 (26.6)
Other 11 (3.1) 19 (5.4) 30 (4.2)
Time since initial diagnosis of breast cancera
Mean (SD), months 24.8 (37.81) 22.4 (29.83) 23.6 (34.02)
Missing, n 9 7 16
Histopathological classification, n (%)
Ductal 278 (79.0) 277 (78.0) 555 (78.5)
Lobular 14 (4.0) 17 (4.8) 31 (4.4)
Unknown 4 (1.1) 3 ( < 1.0) 7 ( < 1.0)
Other 56 (15.9) 58 (16.3) 114 (16.1)
Disease site,b n (%)
Lung 186 (52.8) 185 (52.1) 371 (52.5)
Liver 146 (41.5) 166 (46.8) 312 (44.1)
Lymph node 259 (73.6) 252 (71.0) 511 (72.3)
Skin 45 (12.8) 33 (9.3) 78 (11.0)
Bone 183 (52.0) 177 (49.9) 360 (50.9)
Brain 4 (1.1) 4 (1.1) 8 (1.1)
Breast 192 (54.5) 191 (53.8) 383 (54.2)
Other 68 (19.3) 82 (23.1) 150 (21.2)
Oestrogen receptor status, n (%)
Positive 184 (52.3) 184 (51.8) 368 (52.1)
Negative 168 (47.7) 171 (48.2) 339 (47.9)
Prior trastuzumab exposure, n (%)
Yes 33 (9.4) 39 (11.0) 72 (10.2)
No 319 (90.6) 316 (89.0) 635 (89.8)
ECOG score, n (%)
0 186 (52.8) 194 (54.6) 380 (53.7)
1 150 (42.6) 146 (41.1) 296 (41.9)
2 16 (4.5) 15 (4.2) 31 (4.4)
LVEF result, %
Mean (SD) 65.4 (5.84) 65.3 (6.20) 65.3 (6.02)
ECOG Eastern Cooperative Oncology Group, ITT intent-to-treat, LVEF left ventricular ejection fraction, SD standard deviation, trastuzumab-EU reference
trastuzumab sourced from the European Union
aDefined as time from initial diagnosis to first dose on Cycle 1 Day 1
bData for disease sites recorded as “No” or “Not Assessed” are not presented
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(95% CI: 0.67–1.27; log-rank P= 0.304). Sensitivity analyses of
secondary efficacy endpoints in the PP population yielded results
consistent with those in the ITT population (Supplementary Table S4).
Safety
In the Week 53 analysis, the majority of patients in the safety
population experienced one or more TEAE (337 [96.6%] patients in
the PF-05280014 group and 339 [96.0%] patients in the
trastuzumab-EU group) (Table 3). The incidence for all categories
of TEAEs and serious TEAEs was similar across treatment groups.
The most frequently reported TEAEs (≥ 20% of patients in either
group) were alopecia, anaemia, neutropenia and peripheral
sensory neuropathy. In total, there were 249 (34.5%) patients
with a TEAE reported at Grade 3 or higher, with a similar incidence
across treatment groups. In the PF-05280014 group, there were 86
(24.6%), 18 (5.2%) and 16 (4.6%) patients with maximum Grade 3,
Grade 4 and Grade 5 TEAEs, respectively, and in the trastuzumab-EU
group, the corresponding numbers were 96 (27.2%), 9 (2.5%)
and 24 (6.8%). The most frequently reported TEAE of Grade 3 or
higher in both the PF-05280014 and trastuzumab-EU groups was
neutropenia (35 [10.0%] vs. 28 [7.9%] patients).
Overall, 70 (20.1%) patients in the PF-05280014 group and 73
(20.7%) patients in the trastuzumab-EU group experienced at least
one SAE. The three most frequently reported SAEs were disease
progression (32 [9.2%] patients in the PF-05280014 group vs. 27
[7.6%] patients in the trastuzumab-EU group), pulmonary embo-
lism (5 [1.4%] vs. 3 [0.8%] patients) and pneumonia (4 [1.1%] vs. 3
[0.8%] patients). Of the 85 deaths reported overall (42 [12.0%] vs.
43 [12.2%] patients), 70 were due to MBC (38 [10.9%] vs. 32 [9.1%]
patients).
There were no notable differences between treatment groups
in the incidences of AEs of special interest, including IRRs, cardiac
failure and decreased ejection fraction. The TEAE of IRR was
reported for 34 (9.7%) patients in the PF-05280014 group and 30
(8.5%) patients in the trastuzumab-EU group. Signs and symptoms
of IRRs were collected in addition to the recorded AE of IRR for those
events considered related to PF-05280014 or trastuzumab-EU,
respectively, and were reported for 31 (8.9%) and 27 (7.6%)
patients. The most frequently reported signs and symptoms were
chills (13 [3.7%] vs. 13 [3.7%] patients) and pyrexia (13 [3.7%] vs. 8
[2.3%] patients).
Decreased ejection fraction was reported for 35 (10.0%) patients
in the PF-05280014 group and 39 (11.0%) patients in the
trastuzumab-EU group; four (1.1%) and five (1.4%) patients had
events of Grade 3 or higher, respectively. Mean LVEF values were
generally comparable across treatment groups (Supplementary
Table S5). The TEAE of cardiac failure occurred in five (1.4%)
patients in the PF-05280014 group and seven (2.0%) patients in
the trastuzumab-EU group. With the exception of two patients
with a Grade 3 event (one of which persisted; the outcome of the
other was unknown), the events for the remaining three patients
in the PF-05280014 group were Grade 1 or 2. Two patients in the
trastuzumab-EU group had a Grade 3 event of cardiac failure (one
of which persisted; the other resolved), and two patients had
Grade 5 cardiac failure (one with preceding Grade 4 cardiac
failure); the events for the remaining three patients were Grade 1.
In addition to these TEAEs of cardiac failure, one patient reported
acute cardiac failure (Grade 5) and one patient reported
congestive heart failure (Grade 2; persistent); both patients were
in the trastuzumab-EU group.
No clinically significant differences in laboratory values or
electrocardiogram results were observed between the two
treatment groups.
PK, biomarker and immunogenicity analyses
In the Week 53 analysis, mean trough and peak serum
concentrations in the PK population were similar for both
treatments at all respective time points from baseline up to Cycle
5 Day 8 (Supplementary Figure S1). Per protocol, patients could be
on different regimens of PF-05280014 or trastuzumab-EU (either
weekly or 3-weekly administration) as of Cycle 9 Day 1, but 12
patients were incorrectly switched as early as Cycle 7 Day 1; hence,
concentration comparisons later than Cycle 5 could be con-
founded by the different regimens and are not presented.
The percent change from baseline in serum soluble HER2 ECD
concentrations in the PP population was comparable between the
two treatment groups at all subsequent time points through Cycle
8 (Supplementary Table S6).
In the safety population, 30 (8.6%) patients in the PF-05280014
group and 14 (4.0%) patients in the trastuzumab-EU group tested
positive for ADAs prior to initiation of treatment. Of these, 20
(5.7%) and nine (2.6%) patients, respectively, tested positive for
NAbs. Of the 44 ADA-positive patients at baseline, three patients
in the PF-05280014 group and one patient in the trastuzumab-EU
group reported prior trastuzumab exposure. All patients tested
negative for ADAs after study treatment initiation through
378 days post-randomisation, except two patients (one from each
group). Both these patients tested positive for ADAs and NAbs at
the end-of-treatment visit; no events of IRR or anaphylactic
reaction were reported. One of these two patients was also ADA-
Table 2. Analysis of objective response rate derived from central radiology assessments (ITT population) – Week 33 analysis
PF-05280014 plus paclitaxel
(n= 352)
Trastuzumab-EU plus paclitaxel
(n= 355)
Risk ratio estimate
(95% CI)a
Objective response rateb
n (%) 220 (62.5) 236 (66.5) 0.940
(95% CI) (57.2–67.6) (61.3–71.4) (0.842–1.049)
Best overall response category,c n (%)
Complete response 10 (2.8) 13 (3.7)
Partial response 210 (59.7) 223 (62.8)
Stable disease 76 (21.6) 74 (20.8)
Progressive disease 18 (5.1) 11 (3.1)
Indeterminate 38 (10.8) 34 (9.6)
CI confidence interval, ITT intent-to-treat, RECIST Response Evaluation Criteria in Solid Tumours, trastuzumab-EU reference trastuzumab sourced from the
European Union
aRisk ratio and associated 95% CI were based on the Miettinen and Nurminen16 method
bDefined as the percentage of patients within each treatment group who achieved complete response or partial response by Week 25 that was subsequently
confirmed by Week 33 (or early discontinuation), in accordance with RECIST 1.1
cBest overall response was determined using data up to and including Week 33
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positive and NAb-positive at baseline. Drug concentrations for
both patients were below the lower limit of quantification at the
end-of-treatment visit when ADAs were detected. Prior to the end-
of-treatment visit, serum drug concentrations for both ADA-
positive patients were within the observed concentration range at
corresponding time points for the respective treatment group,
although drug concentrations for the ADA-positive patient in the
trastuzumab-EU group appeared to be at the lower end of the
range for the treatment group.
DISCUSSION
This study demonstrated similarity between PF-05280014 and
trastuzumab-EU in terms of ORR, when each drug was combined
a
HRa 1.00 (95% CI 0.80–1.26)
P-valueb 0.505
b
HRa 1.004 (95% CI 0.655–1.539)
P-valueb 0.507
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Fig. 3 Kaplan–Meier plots of (a) progression-free survival (based on central radiology assessments) and (b) overall survival (ITT population) –
Week 53 analysis. aHRs from a Cox proportional hazards model with prior trastuzumab exposure and oestrogen receptor status as strata.
Assuming proportional hazards, an HR < 1 indicates an increased hazard rate for trastuzumab-EU plus paclitaxel; an HR > 1 indicates an
increased hazard rate for PF-05280014 plus paclitaxel. bOne-sided P value from stratified log-rank test. CI confidence interval, HR hazard ratio,
ITT intent-to-treat, trastuzumab-EU reference trastuzumab sourced from the European Union
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with paclitaxel in the first-line treatment of HER2+MBC. The 95%
CI of the risk ratio for ORR was contained within the pre-specified
equivalence margin.
In terms of methodological strengths, the study used a
randomised, double-blind design and included blinded central
independent radiographic response assessment. The study was
sufficiently powered to demonstrate equivalence in the primary
endpoint, and treatment groups were well-balanced with respect
to baseline clinical, pathologic and demographic factors. The
equivalence design is a robust method for demonstrating that a
potential biosimilar is neither inferior nor superior to the originator
product in a comparative clinical trial.8,9,19 Moreover, ORR is
considered a sensitive endpoint for identifying potential product-
related differences between a potential anti-cancer biosimilar and
the originator,19 as it is a direct measure of drug activity.20
Sensitivity analyses for the efficacy outcomes yielded results that
were consistent with the main findings. The finding of similar peak
and trough levels of PF-05280014 and trastuzumab-EU across
multiple doses complements the PK similarity conclusion of the
previous single-dose PK study in healthy male volunteers.12
The incidence of patients testing positive for ADAs prior to
treatment initiation (8.6% in the PF-05280014 group and 4.0% in
the trastuzumab-EU group) is not without precedent. In an
analysis of the immunogenicity of IV and subcutaneous formula-
tions of reference trastuzumab in the phase III HannaH study, for
example, 5.9% of patients in the IV arm and 4.2% in the
subcutaneous arm were positive for ADAs to trastuzumab at
baseline.21 Indeed, pre-existing ADAs have been detected in
treatment-naïve patients across several biotherapeutic modal-
ities.22 Importantly, in our study, all patients tested negative for
ADAs after study treatment initiation, except two patients (one
from each group). This low incidence of immunogenicity during
treatment in both groups is reassuring, and consistent with results
from other comparative studies of PF-05280014 and reference
trastuzumab, in both healthy volunteers12 and patients with early
breast cancer.13 Overall, the safety findings in the current trial
were consistent with those expected of reference trastuzumab,1,2
with no notable differences between groups.
Although the current study assessed PF-05280014 or
trastuzumab-EU in combination with paclitaxel, current standard
first-line treatment for HER2+MBC involves dual HER2 blockade
with the combination of trastuzumab and pertuzumab added to
chemotherapy.23,24 Additionally, the proportion of patients with
prior treatment with trastuzumab in the study (9.4% in the
Table 3. Summary of treatment-emergent adverse events (safety population) – Week 53 analysis
PF-05280014 plus
paclitaxel (n= 349)
Trastuzumab-EU plus
paclitaxel (n= 353)
Total
(N= 702)
Number of TEAEsa 2336 2436 4772
Patients with event, n (%)
Any TEAEs 337 (96.6) 339 (96.0) 676 (96.3)
Grade 3 or higher TEAEs 120 (34.4) 129 (36.5) 249 (35.5)
Serious TEAEsb 53 (15.2) 56 (15.9) 109 (15.5)
Trastuzumab-related TEAEs 104 (29.8) 101 (28.6) 205 (29.2)
Trastuzumab-related Grade 3 or higher TEAEs 9 (2.6) 11 (3.1) 20 (2.8)
Trastuzumab-related serious TEAEs 5 (1.4) 5 (1.4) 10 (1.4)
TEAEs resulting in permanent discontinuation of
trastuzumab
16 (4.6) 12 (3.4) 28 (4.0)
TEAEs with incidence ≥ 10% in either treatment group,c n (%)
Alopecia 189 (54.2) 185 (52.4) 374 (53.3)
Anaemia 120 (34.4) 131 (37.1) 251 (35.8)
Neutropenia 99 (28.4) 91 (25.8) 190 (27.1)
Peripheral sensory neuropathy 93 (26.6) 83 (23.5) 176 (25.1)
Diarrhoea 56 (16.0) 66 (18.7) 122 (17.4)
Nausea 53 (15.2) 64 (18.1) 117 (16.7)
Asthenia 50 (14.3) 43 (12.2) 93 (13.2)
Fatigue 44 (12.6) 49 (13.9) 93 (13.2)
Headache 41 (11.7) 52 (14.7) 93 (13.2)
Leukopenia 36 (10.3) 41 (11.6) 77 (11.0)
Arthralgia 41 (11.7) 36 (10.2) 77 (11.0)
ALT increased 33 (9.5) 41 (11.6) 74 (10.5)
Ejection fraction decreased 35 (10.0) 39 (11.0) 74 (10.5)
Upper respiratory tract infection 30 (8.6) 40 (11.3) 70 (10.0)
Oedema peripheral 24 (6.9) 43 (12.2) 67 (9.5)
“Trastuzumab” refers to PF-05280014 or trastuzumab-EU.
ALT alanine aminotransferase, MedDRA Medical Dictionary for Regulatory Activities, TEAE treatment-emergent adverse event, trastuzumab-EU reference
trastuzumab sourced from the European Union
aTEAE was defined as any event that occurred on or after the first dose of study treatment administration or any pre-existing event that worsened in severity
after dosing. TEAE was defined through last dose of trastuzumab+ 70 days. For number of TEAEs, the event of “infusion-related reaction” was counted;
however, the number of associated signs and symptoms of infusion-related reactions was counted separately (data not presented)
bSerious TEAE determined by investigator’s assessment of serious
cTEAEs presented in descending order of frequency based on incidence in the total safety population. Patients are only counted once per treatment for each
row. MedDRA (v19.1) coding dictionary applied
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PF-05280014 group and 11.0% in the trastuzumab-EU group) may
be lower than that expected in routine clinical practice in some
countries. However, neither of these factors compromises the
study’s aim of assessing the similarity between PF-05280014 and
trastuzumab-EU.
The ORRs observed in the current study were within the range
of those in previous randomised studies of reference trastuzumab
used in combination with a taxane for first-line treatment of MBC.
For example, in a randomised phase II trial, Gasparini et al17
reported an ORR of 75.0% (95% CI: 62.1–85.3%) in patients treated
with weekly trastuzumab and weekly paclitaxel 80mg/m2. In a
separate randomised phase II trial, Marty et al18 observed an ORR
of 61% (95% CI: 50–71%) in patients treated with weekly
trastuzumab plus 3-weekly docetaxel 100mg/m2. Additionally, in
a randomised phase III trial, Slamon et al3 noted an ORR of 41%
(95% CI: 31–51%) in patients treated with weekly trastuzumab
combined with 3-weekly paclitaxel 175mg/m2. Comparisons of
ORRs across separate trials should be made with caution, however,
because rates could be confounded by differences in patient
characteristics, prior treatment patterns, and methodological
aspects, including the specific dosing regimen and whether
response was assessed centrally or by the investigator.
Regulatory guidance on confirmatory clinical trials of potential
biosimilars recommends conducting such studies in a population
that is sensitive for the detection of product-related differences
between the biosimilar and originator.8,9,19 HER2+MBC is a
condition for which the use of trastuzumab is well-established
and globally accepted. In addition to the current study, MBC has
been used as the setting for comparative clinical studies of other
trastuzumab biosimilars.25,26 One of these, MYL-1401O, was
licensed by the US Food and Drug Administration in December
2017, as trastuzumab-dkst.27 In a randomised trial of 500 patients
without previous treatment for HER2+MBC, this biosimilar
demonstrated equivalence to reference trastuzumab in ORR at
24 weeks, when both treatments were administered 3-weekly and
in combination with a taxane.25 Equivalence was tested via both
the ORR ratio and the ORR difference; the equivalence margin for
the ORR ratio was 0.81–1.24, and was thus similar to the margin
used in our study.25 Another product, BCD-022, demonstrated
non-inferiority to reference trastuzumab in ORR when each
treatment was given 3-weekly in combination with paclitaxel in
a randomised trial of 126 patients with HER2+MBC.26
PF-05280014 has also been compared with trastuzumab-EU in the
neoadjuvant treatment of operable HER2+ breast cancer.13 The
neoadjuvant study was powered to demonstrate non-inferiority of
PF-05280014 to trastuzumab-EU in the proportion of patients with
steady-state trough concentrations > 20 μg/ml; as secondary end-
points, pathologic complete response (pCR) rate and ORR were
found to be similar between treatments.13 These findings in the
sensitive setting of early breast cancer help in addressing concerns
voiced by some commentators regarding the sensitivity and
homogeneity of a population with MBC for an assessment of
potential trastuzumab biosimilars.28 Other trastuzumab biosimilars
have also been studied in the neoadjuvant setting.29–32 ABP 980,
CT-P6 and SB3, for example, all obtained marketing authorisation in
Europe based on submissions that included data from trials
comparing the respective biosimilar with reference trastuzumab
when each was combined with neoadjuvant chemotherapy in an
early breast cancer population.29–35 The primary endpoint in the
trials of ABP 980 and CT-P6 was total pCR rate, while the study of
SB3 utilised breast pCR rate.29,31,32 It should be noted that regulatory
authorities have not specified a preferred setting for comparative
clinical trials of trastuzumab biosimilars, and sponsors are expected
to provide scientific justification for the study design chosen. This
likely explains the differences among the clinical trial designs
adopted for trastuzumab biosimilars.
Biosimilars are expected to have an important role in improving
patient access to biologics and in helping to address increasing
healthcare expenditure; both issues are pressing in the management
of cancer.36–38 In a survey of oncologists from the USA, Mexico,
Turkey, Russia and Brazil, for example, it was reported that access to
trastuzumab was limited by barriers related to insurance coverage,
availability of supply and cost to the patient.6 Approximately half of
respondents reported that they would increase their use of
trastuzumab if a lower-cost biosimilar version were available.6
Indeed, evidence from Europe, where some biosimilars have been
available for >10 years, has identified both increased treatment
utilisation and reduced treatment-day prices following the introduc-
tion of biosimilar competition in several therapeutic classes.39
Comparative clinical studies are the final step in the biosimilar
development process. Rather than seeking to demonstrate de novo
efficacy and safety, such studies aim to confirm a lack of clinically
meaningful differences between the biosimilar and originator
following a demonstration of similarity in earlier studies, including
extensive, foundational structural and functional analyses.8,19 In the
current study, when used as first-line treatment for HER2+ MBC,
PF-05280014 plus paclitaxel demonstrated equivalence to
trastuzumab-EU plus paclitaxel in the primary efficacy endpoint of
ORR, with no notable differences in safety or immunogenicity
profile. Furthermore, no statistically significant differences in PFS, OS
or DOR were observed. As part of the totality of the evidence for
assessing biosimilarity, these results are consistent with, and build
upon, earlier analytical, non-clinical and clinical comparisons of
PF-05280014 and reference trastuzumab.11–13
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